Inogen (INGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Inogen

NasdaqGS•Healthcare•Medical Devices

$5.15+0.02(<0.01%)Market open

Market Cap

$138.74M

P/S

0.4x

P/B

0.8x

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Profitability (16/25); weakest: Cash & Earnings Quality (6/25).

Profitability16/25

Growth12/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 87.6x5y range 87.6x – 87.6x

P/S · 0.4x5y range 0.4x – 2.8x

Currently below its 20-quarter median.

P/B · 0.8x5y range 0.5x – 2.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $138.74M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $354.30M
Q. Revenue: $95.08M
TTM EBITDA: $-11.00M
TTM Op. Income: $-30.85M
Q. Op. Income: $-5.10M
TTM Net Income: $-24.59M
Q. Net Income: $-3.85M
EPS: $-0.14
Shares Out.: $27.05M

$354.30M in TTM revenue grew 3.2% YoY, reaching $95.08M last quarter. TTM EBITDA of $-11.00M and TTM operating income of $-30.85M show growth is flowing through to the bottom line. However, net income is negative at $24.59M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 45.5%
EBITDA Margin: -0.4%
Op. Margin: -5.4%
Net Margin: -4.0%

Op. margin of -5.4% is up 1.3% YoY — cost efficiency is improving. Net margin at -4.0% and gross margin of 45.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.4x
P/B Ratio: 0.8x

P/S of 0.4x and P/B of 0.8x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $285.57M
Cash: $87.28M
Long-Term Debt: N/A
Book Value: $174.86M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $2.95M
TTM Free Cash Flow: $-4.98M
FCF Margin: -1.4%
FCF / Net Income: 0.2

TTM FCF of $-4.98M on $2.95M in operating cash flow. The FCF / Net Income ratio of 0.2x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 56% — a weakening trend.